is rybelsus glp 1 Health Canada approves Rybelsus, the first oral GLP-1 pill to lower cardiovascular risk in adults with Type 2 diabetes. #longevity #GLP1 #diabetes #cardiometabolic #hearthealth #metabolichealth #obesitycare #digitalhealth #biotechnews #healthinnovation RYBELSUS® (semaglutide) tablets 7 mg

According to the manufacturer, the product is described as featuring: A plant-based formula Transdermal application format Ingredients including berberine and chromium The manufacturer states the patches are designed with the goal of supporting: Appetite signaling pathways Metabolic function Balanced wellness Manufacturing Context (Per the Company) According to the NuraPatch FAQ, the product is "made in facilities that follow FDA guidelines for dietary supplements." The company states that as a "plant-based wellness product and not a prescription drug, it does not need separate FDA approval for drugs." This language aligns with standard dietary supplement regulatory positioning under the Dietary Supplement Health and Education Act (DSHEA)

And could they extend not just metabolic health, but also healthspanthe years lived in good health

[DOI] [PubMed] [Google Scholar] Moran JA, Dahl EL, et al

Di Lisa F, Carpi A, Giorgio V, Bernardi P

Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials